Puma Biotech (PBYI) Reports Positive PB272 Phase II Data from TBCRC 022 Trial in Patients with HER2-Positive Metastatic Breast Cancer with Brain Metastases at ASCO Meetings
Tweet Send to a Friend
Puma Biotechnology, Inc. (NASDAQ: PBYI) announced the presentation of positive results from an ongoing Phase II clinical trial (Translational Breast ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
